Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
Cancer Management and Research|July 15, 2014
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscapeNeeharika Srivastava, David McDermottExpert Opinion on Biological Therapy|December 9, 2023
Adjuvant immunotherapy for locally advanced renal cell carcinomaMichail Alevizakos, David McDermottTherapeutic Advances in Urology|December 2, 2015
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaMatthew Weinstock, David McDermottStudies in Health Technology and Informatics|September 14, 2004
Improving cancer related symptom management with collaborative healthwareDenise Goldsmith, David McDermott, Charles SafranCancer|July 19, 2019
To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune diseaseMorgan Pantuck, David McDermott, Alexandra DrakakiCurrent Urology Reports|February 17, 2006
Designing clinical trials for kidney cancer based on newly developed prognostic and predictive toolsDaniel Cho, David McDermott, Michael AtkinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinomaMichael B Atkins, Meredith Regan, David McDermottClinical Genitourinary Cancer|June 8, 2007
What is standard initial systemic therapy in metastatic renal cell carcinoma?Brian I Rini, David McDermott, Michael AtkinsBMJ Supportive & Palliative Care|March 5, 2017
Developing a model for embedded palliative care in a cancer clinicSusan DeSanto-Madeya, David McDermott, Jessica A Zerillo, et al.Urologic Oncology|October 8, 2010
Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review studyToni K Choueiri, David McDermott, Mei Sheng Duh, et al.Pageof 6